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Background: Exercise and diet control are 
fundamental approaches to metabolic conditions 
caused by high fat diet (HFD). 
Results: HFD-induced memory deficit and A 
deposition was more ameliorated in the exercise- 
than in the diet control-induced mice. 
Conclusion: Exercise was more effective than 
diet control in preventing HFD-induced AD 
development. 
Significance: Exercise has the highest priority in 
the prevention of AD. 
 
Summary 
Accumulating evidence suggests 
that some dietary patterns, specifically high fat 
diet (HFD), increase the risk of developing 
sporadic Alzheimer disease (AD). Thus, 
interventions targeting HFD-induced 
metabolic dysfunctions may be effective in 
preventing the development of AD. We 
previously demonstrated that amyloid 
precursor protein (APP)-overexpressing 
transgenic mice fed HFD showed worsening of 
cognitive function compared to control APP 
mice on normal diet. Moreover, we reported 
that voluntary exercise ameliorates 
HFD-induced memory impairment and 
-amyloid (A) deposition. In the present 
study, we conducted diet control to ameliorate 
the metabolic abnormality caused by HFD on 
APP transgenic mice and compared the effect 
of diet control on cognitive function to that of 
voluntary exercise as well as that of combined 
(diet control plus exercise) treatment. 
Surprisingly, we found that exercise was more 
effective than diet control, although both 
exercise and diet control ameliorated 
HFD-induced memory deficit and A 
deposition. The production of A was not 
different between the exercise- and the diet 
control-treated mice. On the other hand, 
exercise specifically strengthened the activity 
of neprilysin, the A degrading enzyme, the 
level of which was significantly correlated with 
that of deposited Ain our mice Notably, the 
effect of the combination treatment (exercise 
and diet control) on memory and amyloid 
pathology was not significantly different from 
that of exercise alone. These studies provide 
solid evidence that exercise is a useful 
intervention to rescue HFD-induced 
aggravation of cognitive decline in 
transgenic model mice of AD.              
 
Alzheimer disease (AD), the most 
common cause of dementia, is poised to be a 
significant public health crisis. The occurrence of 
AD is largely sporadic, typically affecting 
individuals aged over 65 years. Amyloid plaque is 
one of the pathological hallmarks of AD. 
Amyloid plaques are composed of -amyloid 
(A), which are derived from the amyloid 
precursor protein (APP) via proteolytic cleavages 
by - and γ-secretases. A widely accepted 
hypothesis about AD pathogenesis is the amyloid 
cascade hypothesisin which A plays a crucial 
role in neurodegeneration [1]. Importantly, 
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recent studies have implied that soluble 
Aoligomers may be the main culprit of AD 
pathogenesis [2-4]. 
High fat diet (HFD) is prevalent in 
modern society and HFD-induced metabolic 
condition is becoming a worldwide issue since 
it leads to obesity, type 2 diabetes mellitus 
(T2DM) and hypercholesterolemia. More 
importantly, accumulating evidence suggests that 
some dietary patterns, specifically HFD, increase 
the risk of developing sporadic AD [5]. 
Experimental studies also support this idea. For 
example, application of HFD for APP 
transgenic mice exacerbated pathological 
alterations in the brain and their memory 
deficits [6, 7]. In contrast, it is widely known 
that composite dietary patterns such as the 
Mediterranean diet, characterized by high 
intake of vegetables, unsaturated fatty acids 
and wine, are related to lower risk for AD [8]. 
These reports clearly indicate that there is an 
association between metabolic conditions and a 
higher risk of sporadic AD. 
Exercise and diet control are 
fundamental approaches in the treatment of 
metabolic conditions. They might also become 
useful ways to prevent the development of AD. 
For example, a prospective study revealed that 
physical activity is protective against the 
development of cognitive impairment in AD 
and that the highest activity group showed a 
lowered incidence of AD [9]. Recently, we also 
demonstrated that voluntary exercise 
ameliorates HFD-induced memory deficit and 
A deposition in APP transgenic mice [7], 
indicating that interventions to reduce 
metabolic conditions can become the 
preventive method for AD. However, it still 
remains unknown what kind of intervention 
targeting metabolic conditions is more effective. 
In the present study, we used the AD 
model mice with metabolic conditions through 
HFD (APP-HFD mice), which we had previously 
established [7]. In addition to voluntary exercise, 
we preventively conducted diet control or the 
combination of diet control with exercise using 
APP-HFD mice, followed by comparing the 
effect of these interventions on cognitive function 
and amyloid pathology. Here, we show that diet 
control improved metabolic conditions including 
hyperinsulinemia and hypercholesterolemia of 
APP-HFD mice better than exercise. However, 
exercise more effectively ameliorated 
HFD-induced memory deficit and A deposition 
than diet control (in spite of higher serum 
insulin/cholesterol levels). Exercise specifically 
enhanced the activity of neprilysin, which we 
speculate may be responsible for the reduction of 
the A level. These results clearly indicated that 
exercise, affecting the process of Adegradation, 
could be a more effective way to ameliorate the 
AD progression caused by metabolic 
dysfunctions than diet control. 
 
Experimental Procedure 
Animals and dietary conditions 
Human APP transgenic mice 
overexpressing the familial AD-linked 
mutations bearing both Swedish 
(K670N/M671L) and Indiana (V717F) 
mutation (APPSwe/Ind) [10], which have been 
imported from the Jackson Laboratory (USA) 
were used in the present study. They were 
maintained as heterozygotes and male and 
female mice were housed separately. Age- and 
sex-matched (1:1, male: female) mice were 
exposed to either a standard diet (10% fat, 70% 
carbohydrate, and 20% protein, Oriental Yeast 
Co., Ltd., Japan) or an established high fat diet 
(HFD) (caloric composition, 60% fat, 20% 
carbohydrate, and 20% protein, Research Diet, 
Inc., Canada) for 20 weeks, from 2-3 to 7-8 
months age. To examine the effect of 
voluntary exercise (Ex) on APP transgenic 
mice fed HFD (APP-HFD mice), the cage of 
the mice was changed to a 2.4 times larger one 
equipped with a running wheel as well as 
objects after 10 weeks of HFD (APP-HFD+Ex 
mice) [7]. The mice spent 10 weeks in the 
exercise condition in the presence of HFD. To 
examine the effect of diet control (Dc) on 
APP-HFD mice, HFD was replaced to standard 
diet after 10 weeks of HFD and fed with 
standard diet for another 10 weeks 
(APP-HFD+Dc mice). To examine the effect of 
the combinatory intervention of Ex and Dc, the 
mice were spent 10 weeks in the exercise 
condition in the presence of standard diet after 
10 weeks of HFD (APP-HFD+Ex+Dc mice).  
After the dietary manipulation, metabolic 
changes in these mice were analyzed, followed 
by the assessment of memory function through 
the Morris water maze test, as described below. 
After the analysis of memory function, the 
brains were extracted and were cut sagitally 
into left and right hemispheres. The left 
hemisphere was fixed in 4% paraformaldehyde 
for histological analysis. After removing the 
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olfactory lobe and cerebellum, the right 
hemisphere was rapidly frozen in liquid 
nitrogen for biochemical analysis. All animal 
experiments were performed in compliance with 
the Guidelines for the Care and Use of 
Laboratory Animals of the Kyoto University. 
 
Assessment of metabolic changes 
Blood glucose content was 
measured by using LabAssay Glucose (Wako, 
Japan). To assess glucose intolerance in these 
mice, we conducted the intra-peritoneal glucose 
tolerance test (IGTT). Mice were given a single 
dose of intra-peritoneal injection of glucose (2 
g/kg body weight) after 14 hours fasting, and 
blood was collected from the tail-vein 
periodically over 2 hours (fasting, 30 min, 60 
min and 120 min). Plasma insulin 
concentration was measured by enzyme-linked 
immunosorbent assay (ELISA) kit specific to 
insulin (Morinaga Seikagaku, Japan). Plasma 
concentrations of total cholesterol, high 
density lipoprotein (HDL)-cholesterol and 
triglyceride were measured by using 
cholesterol E-Wako, HDL-cholesterol E-Wako 
and triglyceride E-Wako (Wako, Japan). 
 
Morris water maze test 
In order to assess spatial navigation 
learning and memory retention, the Morris 
water maze test was conducted. Initially, 
animals received a habituation trial during 
which the animals were allowed to explore the 
pool of water (diameter 120 cm, height 25 cm, 
temperature 21±1°C) without the platform 
present.  
Visual cue phase. Following 
habituation, visible platform training was 
performed to measure motivation and 
swimming speed of mice to find a platform. 
Briefly, distal cues were removed from around 
the pool, and the platform was labeled with a 
flag and placed 1 cm above the surface of the 
water in the center of a quadrant. Mice were 
placed in the maze and allowed to explore the 
maze for 60 sec, and if they reached the visible 
platform, they were allowed to remain there 
for 20 sec before being returned to their cages. 
If they did not find the platform within 60 sec, 
the experimenter led them to the platform and 
let them remain there for 20 sec. Animals were 
trained in groups of five, and training was 
completed once each animal received six trials. 
This training was performed for 1 day.  
Acquisition phase. We measured 
the ability of mice to understand the spatial 
relationship between a safe, but invisible 
platform of 10 cm in diameter (submerged 1 
cm below the water level), and visual cues 
surrounding the maze. The platform was 
located in the center of one of the four 
quadrants, and several extramaze cues were 
distributed across the walls surrounding the 
pool. During the acquisition phase of training, 
each mouse received four daily hidden 
platform training trials with 10-12 min 
intervals for 5 consecutive days. Animals were 
allowed 60 sec to locate the platform and 20 
sec to rest on it. Mice that failed to find the 
platform were led there by the experimenter 
and allowed to rest there for 20 sec.  
Probe trial phase. 24 hours 
following the last acquisition trial, a single 60 
sec probe trial was administered to assess 
spatial memory retention. For the probe trial, 
animals were returned to the pool without the 
platform present, and parameters were 
recorded to assess the ability of the mouse to 
remember the previous location of the 
platform.  
Performance was recorded with an 
automated tracking system (TARGET series/2, 
Japan) during all phases of training. During the 
visual cue phase of training, speed and latency 
to the platform were used to compare the 
activity of the performance between each 
group. During the acquisition phase, 
acquisition time (latency to reach the platform) 
and path length (total distance travelled) were 
subsequently used to analyze and compare the 
performance between different treatment 
groups. The time to the platform quadrant, and 
the number of entries into the target quadrant 
were recorded and analyzed during the probe 
trials. 
 
Immunoblotting and filter trap assay 
For immunoblotting analysis, the 
brain was taken and rapidly frozen using liquid 
nitrogen. The brain samples from the cerebrum 
of the male mice were extracted in 
radio-immunoprecipitation assay (RIPA) buffer 
(50 mM Tris-HCl, 150 mM NaCl, 1% Triton 
X100, 1% NP-40, 0.5% Deoxycholate, 0.1% 
SDS, pH 8.0) with protease inhibitor cocktail 
(Roche) and sufficiently homogenized on ice. 
Then the samples were incubated for one night at 
4ºC and centrifuged at 14,000 g for 20 min. The 
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supernatants were directly used for Western blot 
analysis. The detailed protocol has been 
described previously [11]. 5-20 % 
polyacrylamide gradient gels (Atto) were used to 
detect full length APP, -actin, neprilysin and 
insulin-degrading enzyme. Both 5-20 % 
polyacrylamide gradient gels (Atto) and 4-12% 
NuPAGE Bis-Tris gel (Invitrogen) were used to 
detect APP CTFs. Mouse monoclonal anti- 
-actin and rabbit polyclonal anti-APP C-terminal 
antibodies were from SIGMA. Rabbit polyclonal 
anti-neprilysin and mouse monoclonal 
anti-insulin degrading enzyme antibodies were 
from Abcam. 
Filter trap assay was conducted as 
described previously [7, 12]. Briefly, the 
protein concentration of the cerebrum samples 
in Tris-buffered saline (TBS)-extracted 
fraction was measured and an equal amount of 
protein was subjected to vacuum filtration 
through a 96-well dot blot apparatus (Bio-Rad 
Laboratories) containing 200 nm pore-sized 
nitrocellulose membrane. The resultant 
membrane was then incubated with primary 
antibody at 4°C overnight. The membrane was 
then blocked by TBS containing 4% skim milk, 
and incubated with HRP-linked secondary 
antibody (GE Healthcare; diluted 1:2000) for 1 
hour. The membrane was developed using the 
ECL Western Blotting Analysis System (GE 
Healthcare). Anti-Aβ oligomer antibody (A11, 
Invitrogen) was used for the detection of Aβ 
oligomer in TBS soluble fraction. 
 
Immunohistochemistry 
The paraformaldehyde-fixed and 
paraffin-embedded tissue sections of male mice 
were incubated with primary antibodies. The 
sections were then incubated with biotinylated 
anti-second IgG antibody (1:2,000; Vector 
Laboratories), followed by the incubation with 
avidin peroxidase (ABC Elite kit; 1:4,000; Vector 
Laboratories). Subsequently, the labeling was 
visualized by incubation with 50 mM Tris-HCl 
buffer (pH 7.6) containing 0.02% 
3,3-diaminobenzidine and 0.0045% hydrogen 
peroxide. All images were visually analyzed 
using a microscope, ECLIPSE 80i (Nikon 
Corporation). For each animal, the sections of the 
hippocampus were captured then were imported 
into Image J, and an intensity threshold level was 
set that allowed for discrimination between the 
antigen and background labeling. 
Anti-AEantibody (1:1,000; SIGMA) was 
used for the detection of Aplaque. 
 
Neprilysin activity assay 
The proteolytic activity of neprilysin 
was measured as described previously with minor 
modifications [13]. Briefly, the brain samples 
from the cerebrum of the male mice were 
extracted in RIPA buffer and protein 
concentrations were analyzed. 100 μg of brain 
lysates were incubated with 50 μM the 
substrate3-dansyl-D-Ala-Gly-p-(nitro)-Phe-Gly 
(DAGNPG) (SIGMA) and 1μM captopril, 
angiotensin converting enzyme (ACE) inhibitor, 
in 200 μl of 50 mM Tris-HCl buffer (pH 7.6) for 
1 hr at 37℃. Reactions were stopped by heating 
samples to 100℃ for 5 min, followed by 5000 g 
x 5 min centrifugation. The 180 μl of supernatant 
was diluted into 400 μl of 50 mM Tris-HCl buffer 
(pH 7.6) and fluorescence was determined using 
Infinite 200 PRO (Tecan Japan Co., Ltd.) 
(excitation 342 nm, emission 562 nm). 
 
Statistical analysis 
All values are given in means ± SE. 
Comparisons were performed using an unpaired 
Student’s t-test. For comparison of 
multiparametric analysis, one-way factorial 
ANOVA, followed by the post hoc analysis by 
Fisher’s PLSD was used. Statistical significance 
of differences between mean scores during 
acquisition phase of training in the Morris 
water maze test was assessed with two-way 
repeated-measures ANOVA (general linear 
model/RM-ANOVA) and Fisher’s post hoc 
analysis for multiple comparisons. p < 0.05 was 
considered to indicate a significant difference.  
 
Results 
Effects of diet control on the metabolic 
conditions of APP-HFD mice 
In our recent literature, voluntary 
exercise is shown to be a useful tool for 
preventing the progress of cognitive dysfunction 
and amyloid pathology in APP-HFD mice [7]. 
Notably, voluntary exercise does not ameliorate 
HFD-induced hyperinsulinemia or 
hypercholesterolemia but improves glucose 
intolerance as well as cognitive impairment. 
Diet therapy is another way to control metabolic 
dysfunctions. Thus, in the present study, we 
aimed to elucidate which environmental factor 
contributes more to metabolic and cognitive 
functions in APP-HFD mice by controlling the 
diet (Dc; diet control, APP-HFD+Dc) or 
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combined diet control with exercise (Ex; exercise, 
APP-HFD+Ex+Dc) after mice were fed HFD for 
10 weeks. Then, we compared the effects of these 
interventions on cognitive function and A 
pathology (Fig. 1A).  
As reported previously, APP-HFD 
mice gained significantly more body weight 
than the control APP mice and after the 
introduction of voluntary exercise 
APP-HFD+Ex mice gained less body weight 
than APP-HFD mice [7]. On the other hand, 
the body weight decrease of APP-HFD+Dc and 
APP-HFD+Ex+Dc mice was much more drastic 
than that of APP-HFD+Ex mice (Fig. 1B), 
showing that diet control was more effective in 
body weight reduction than voluntary exercise. 
Weekly monitoring of food intake showed that 
the food intake of the APP-HFD+Dc and 
APP-HFD+Ex+Dc mice did not change or 
mildly increased (supplemental Fig. 1), 
indicating that the diet control-mediated 
attenuation of body weight was not caused by 
the reduction of food intake. Fasting serum 
glucose level was not different among 
APP-HFD+Ex, APP-HFD+Dc and 
APP-HFD+Ex+Dc mice, being significantly 
lower in the three groups than that in APP-HFD 
mice (Fig. 1C. pre). In addition, the result of 
IGTT indicated that the impaired glucose 
tolerance was improved in the APP-HFD+Ex 
as well as APP-HFD+Dc and APP-HFD+Ex+Dc 
mice (Fig. 1C). To examine whether diet 
control reverses or prevents the development 
of glucose intolerance, we conducted IGTT 10 
weeks after HFD introduction (at the time 
point when exercise or diet control was started). 
The fasting glucose level and glucose tolerance 
of APP-HFD+Dc and APP-HFD+Ex+Dc mice 
were better than those of APP mice 10 weeks 
after HFD introduction (supplemental Fig. 2). 
Therefore, diet control reversed glucose 
intolerance as well as exercise did [7]. The 
plasma insulin level of APP-HFD+Dc and 
APP-HFD+Ex+Dc mice was significantly 
decreased compared with that of APP-HFD mice 
(Fig. 1D). The plasma lipid analyses indicated 
that both total and HDL-cholesterol were 
significantly decreased in APP-HFD+Dc and 
APP-HFD+Ex+Dc mice (Fig. 2A and B), 
suggesting that diet control ameliorated 
HFD-induced hypercholesterolemia. The level of 
plasma triglycerides was not different among 
them (Fig. 2C).  
 
Exercise was more effective in ameliorating 
memory deficit of APP-HFD mice than diet 
control 
To compare the effect of diet 
control on HFD-induced memory deficit with 
that of exercise, we conducted the Morris 
water maze test. The locomotor activity of 
APP mice was not affected by HFD, HFD+Ex, 
HFD+Dc or HFD+Ex+Dc as exemplified by 
swimming speed (supplemental Fig. 3). During 
the acquisition phase, APP-HFD+Ex, 
APP-HFD+Dc and APP-HFD+Ex+Dc mice 
showed a daily improvement in their 
acquisition time. However, APP-HFD+Dc 
mice took longer time to reach the goal than 
APP-HFD+Ex mice did (Fig. 3A). In the probe 
trial phase, the time to get to the platform 
quadrant in APP-HFD+Dc mice was 
significantly longer than that in APP-HFD+Ex 
mice (Fig. 3B). Moreover, the number to cross 
the previous location of the platform in 
APP-HFD+Dc mice was significantly smaller 
than that in APP-HFD+Ex mice (Fig. 3C). 
These results demonstrated that APP-HFD+Dc 
mice took a longer time to get to the platform 
quadrant and failed to cross the previous 
location of the platform compared to 
APP-HFD+Ex mice. From these results, we 
concluded that exercise was the more effective 
way of ameliorating HFD-induced memory 
dysfunction than diet control in APP-HFD 
mice. 
 
The Aβ pathology of APP-HFD mice was 
ameliorated better by exercise than by diet 
control 
Since ample Aβ deposition is a 
critical hallmark of AD, we compared the 
effect of diet control on HFD-induced Aβ 
accumulation with that of exercise. For this, 
we conducted immunohistochemical analysis 
using anti-Aβ (6E10) antibody to 
quantitatively examine Aβ deposition. As 
shown in Fig. 4A, Aβ deposition was 
aggravated by feeding HFD [7], whereas 
marked reduction of HFD-induced Aβ 
deposition was observed in APP-HFD+Ex, 
APP-HFD+Dc and APP-HFD+Ex+Dc mice. 
Interestingly, the level of deposited Aβ in 
APP-HFD+Ex was significantly lower than 
that in APP-HFD+Dc mice (Fig. 4B). 
Therefore, exercise was more effective in 
reducing Aβ accumulation than diet control. 
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Increasing reports show that the 
level of TBS-soluble Aβ oligomers correlate with 
memory deficits in AD model mice [2-4]. We 
showed that HFD increases the level of soluble 
Aβ oligomers in APP mice, which is reduced by 
voluntary exercise [7]. We further extended this 
result by comparing the amount of Aβ oligomers 
in the above three conditions. The filter trap 
analysis indicated that the levels of Aβ 
oligomers in the APP-HFD+Ex, APP-HFD+Dc 
and APP-HFD+Ex+Dc mice were all 
significantly decreased, compared with the 
level in the APP-HFD mice (Fig. 4C and D). 
Remarkably, the level of Aβ oligomers in the 
APP-HFD+Ex mice was statistically lower 
than that in APP-HFD+Dc mice. Thus, 
exercise plays a much more significant role 
than diet control in APP-HFD mice in 
modulating not only Aβ deposition but also the 
level of Aβ oligomers. This is in line with the 
result of behavioral experiments.  
 
HFD-enhanced APP processing was equally 
inhibited by exercise and by diet control 
The above results led us to wonder 
whether the level of Aβ in our mice was 
regulated by APP processing or by Aβ 
degradation in exercise/diet control conditions. 
In order to examine how these environmental 
conditions affected the HFD-induced Aβ 
pathology, we first investigated the effect on 
APP processing in both conditions and 
compared the result of exercise with that of diet 
control. For this, we analyzed the level of APP 
C-terminus fragments through immunoblotting 
assay using anti-APP C-terminal antibody. 
APP is cleaved by -and-secretases at the 
extramembrane domain, which produce 
APP-CTFand CTF respectively. 
APP-CTFand CTFwere further cleaved by 
γ-secretase at the intramembrane domain, 
producing p3 and Aβ respectively. In the 
present study, the level of full length APP was 
not different among control-APP, APP-HFD, 
APP-HFD+Ex, APP-HFD+Dc and 
APP-HFD+Ex+Dc mice (Fig. 5A and B). 
Moreover, the change of fully glycosylated 
form was not observed among them. On the 
other hand, the level of APP-CTF in the 
APP-HFD mice was higher than that in the 
control APP, APP-HFD+Ex, APP-HFD+Dc 
and APP-HFD+Ex+Dc mice. Notably, the 
level of APP-CTF in APP-HFD+Ex was the 
same as that in APP-HFD+Dc mice (Fig. 5A 
and C), indicating that both exercise and diet 
control inhibited -secretases-mediated APP 
cleavage. This tendency was also observed in 
the level of APP-CTF(Fig. 5A and D) 
 
Neprilysin activity was up-regulated by exercise  
Next, we examined the effect of 
environmental intervention on Aβ degradation 
process in APP-HFD mice. Aβ-degrading 
proteases, including neprilysin, were reported to 
degrade Aβ both in vitro and in vivo [14, 15]. To 
compare the effect of exercise on the degradation 
of Aβ with that of diet control, we analyzed the 
enzymatic neprilysin activity. As shown in Fig. 
6A, the activity of neprilysin had a tendency to be 
suppressed by HFD although it did not reach 
statistical significance. More importantly, the 
enzymatic activity of neprilysin in APP-HFD+Ex 
mice was significantly higher than that in 
APP-HFD+Dc mice. On the other hand, the 
neprilysin activity in APP-HFD+Dc mice was the 
same as that in APP-HFD mice. These results 
indicated that exercise could up-regulate the 
enzymatic activity of neprilysin. To clarify 
whether the up-regulation of neprilysin depended 
on its expression level, we conducted 
immunoblotting assay. As shown in supplemental 
Fig. 4, the levels of neprilysin were not different 
among APP-HFD, APP-HFD+Ex, APP-HFD+Dc 
and APP-HFD+Ex+Dc mice, although those 
were slightly larger than that in control APP mice. 
In addition, we examined the expression levels of 
insulin-degrading enzyme, another Aβ-degrading 
protease, and indicated that its levels were also 
not different among APP-HFD, APP-HFD+Ex, 
APP-HFD+Dc and APP-HFD+Ex+Dc mice. In 
order to confirm the effect of neprilysin activity 
on the Aβ deposition in our mice, we conducted 
correlation analysis between neprilysin activity 
and the level of Aβ plaque. The activity of 
neprilysin was significantly correlated with the 
level of Aβ deposition (Fig. 6B).  
 
Discussion 
HFD is prevalent in modern 
society and HFD-induced metabolic conditions 
are becoming a worldwide issue. Notably, 
increasing reports have suggested that diet and 
nutrition are important epigenetic factors for the 
development of sporadic AD  [16-18]. Several 
epidemiological studies have reported that 
people with a higher body mass index (BMI) 
during midlife are at greater risk for 
developing AD [19-21] and that obesity is 
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associated with lower brain volumes in 
patients with mild cognitive impairment (MCI) 
or AD [22]. Obesity promotes a cascade of 
pathological conditions including T2DM and 
dyslipidemia. Remarkably, several drugs 
targeting T2DM and hypercholesterolemia have 
been shown to improve cognitive performance in 
mouse models of AD as well as in patients with 
early AD [23-26]. In our experiment, serum 
glucose, serum insulin and serum cholesterol 
levels were positively correlated with the result of 
Morris test in APP-HFD mice, confirming that 
both T2DM and hypercholesterolemia could 
deteriorate memory deficit in APP mice 
(supplemental Fig. 5). However, serum 
glucose level was correlated with memory 
function in APP-HFD mice better than serum 
cholesterol and serum insulin levels. In 
addition, we previously demonstrated that 
exercise in our experimental condition does 
not improve HFD-induced hyperinsulinemia 
and hypercholesterolemia but ameliorates 
glucose intolerance [7]. Therefore, the 
intervention to hyperglycemia and glucose 
intolerance might be important for the 
prevention of AD.  
Magkos et al. reviewed that first-line 
intervention to metabolic dysfunctions involves 
lifestyle modifications including diet control and 
physical activity, and that metabolic dysfunctions 
may be reversible if addressed early on. They 
proposed that long-term engagement in lifestyle 
changes may result in the resolution of such 
dysfunctions [27]. However, there has been no 
solid evidence on whether diet control or exercise 
is more effective in the prevention of AD. 
Therefore, in the present study, we aimed to 
compare the effect of diet control on metabolic 
dysfunctions as well as AD pathology with that of 
exercise using APP-HFD mice. Our present study 
clearly revealed that exercise ameliorated 
HFD-induced memory impairment better than 
diet control (Fig. 3). Exercise is reported to 
enhance neurogenesis and results in increased 
numbers of synapses per neuron [28]. In 
addition, exercise increases the expression of 
the brain-derived neurotrophic factor (BDNF), 
which regulates neuronal development as well 
as plasticity [29]. In this sense, exercise might 
specifically induce ‘cognitive reserve’ which 
increases cognitive function and enhances 
complex mental activity as protective factors 
against dementia  [reviewed in 30]. On the 
other hand, we showed that exercise decreased 
the level of soluble Aβ oligomers as well as 
deposited Aβ more than diet control (Fig. 4). 
Thus, the exercise-induced inhibition of Aβ 
oligomers might be involved in better cognitive 
performance in APP-HFD mice, since the level 
of soluble Aβ oligomers is known to correlate 
with memory deficits due to their synaptotoxicity 
[2-4]. In line with our present result, Hu et al. 
previously showed that exercise reduces 
oligomeric Aβ levels in the cortex and 
hippocampus of AD model mice [28]. 
However, there are a couple of differences 
between our experimental conditions and theirs. 
Our mice were fed HFD but their mice were 
given a standard diet. Moreover, we analyzed 
oligomeric Aβ levels after onset of Aβ 
deposition but they examined them before Aβ 
accumulation. Therefore, our results clearly 
supported that exercise reduced oligomeric Aβ 
levels after onset of Aβ deposition even if the 
mice were fed with HFD.  
The level of A within the brain is 
determined by the balance between its production 
and its degradation. Since A is generated by the 
proteolytic processing of APP, we first examined 
whether exercise or diet control was acting 
directly on A production. Our detail 
immunoblotting analysis showed that the level of 
APP CTFin APP-HFD+Ex mice was almost 
the same as that in APP-HFD+Dc mice (Fig. 
5), indicating that the production of Aβ might 
not be different between APP-HFD mice treated 
with exercise and those treated with diet control. 
On the contrary, the enzymatic activity of 
neprilysin, the Aβ degrading enzyme, was 
up-regulated in APP-HFD+Ex mice more than in 
APP-HFD+Dc mice (Fig. 6). Lazarov et al. 
have reported that voluntary exercise elevates 
neprilysin activity in the brain of APP 
transgenic mice, contributing to the lowering 
of Aβ levels [31], which is in line with our 
findings. However, their result is different from 
ours in that their APP mice which were 
allowed voluntary exercise, were fed a 
standard diet. Intriguingly, we found that 
feeding HFD itself reduced the activity of 
neprilysin. We further observed that exercise 
strengthened neprilysin activity even if the 
mice were fed with HFD. In the present study, 
the activity of neprilysin was negatively 
correlated with the level of deposited Aβ (Fig. 
6). Therefore, we assumed that 
exercise-mediated up-regulation of neprilysin 
may critically reduce HFD-induced Aβ 
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deposition. Importantly, the expression level of 
neprilysin did not change between the exercise- 
and the diet control-treated APP-HFD mice 
(supplemental Fig. 4). Since the activity of 
neprilysin was clearly up-regulated by exercise 
only, we concluded that exercise could modulate 
its activity in an expression level independent 
manner. We speculate that exercise may 
specifically modulate the up-stream molecules of 
neprilysin or may regulate posttranslational 
modification of neprilysin. The mechanism of 
neprilysin up-regulation by exercise should be 
clarified in the future studies. 
As classified in Fig. 7A, our result, 
for the first time, clarified the differential 
effects of diet control and exercise on 
metabolic and cognitive dysfunctions. 
According to our data, diet control significantly 
improved HFD-induced metabolic conditions, 
including obesity, hyperinsulinemia and 
hypercholesterolemia (Fig. 1 and 2), compared 
with exercise. However, exercise decreased Aβ 
oligomers as well as deposited Aβ (Fig. 4) and 
ameliorated memory impairment (Fig. 3) 
compared with diet control. From these results, 
we conclude that exercise was more effective 
than diet control in the prevention of 
HFD-induced amyloid pathology. In Fig. 7B, 
we present our hypothesis on how diet control 
and exercise differently ameliorate HFD-induced 
Aβ deposition and memory deficit in APP 
transgenic mice. As described in our previous 
literature, HFD leads to glucose intolerance and 
hyperglycemia, which may lead to the 
up-regulation of -secretase activity. This 
up-regulation increases soluble Aβ oligomers as 
well as deposited Aβ levels, followed by memory 
deficit [7]. The up-regulation of β-secretase was 
also reported in HFD-feeding mice from another 
laboratory [32], and consistently reported in AD 
cases by several previous reports [33-35]. Thus, 
this phenomenon might represent the actual 
pathology of sporadic AD. On the other hand, 
both diet control and exercise ameliorate 
HFD-induced glucose intolerance and 
hyperglycemia, thereby decreasing Aβ load by 
inhibiting Aβ production. However, exercise 
specifically strengthens the enzymatic activity of 
neprilysin, which decreases the level of Aβ in the 
brain. Surprisingly, the effect of the combination 
treatment (exercise and diet control) on cognitive 
function and amyloid pathology was not 
significantly different from that of exercise only, 
indicating that exercise is an effective behavioral 
intervention sufficient to inhibit Aβ pathology. 
We suppose this is because exercise affects both 
the production and the degradation of Aβ, but diet 
control modifies only the production of Aβ. 
Therefore, for the introduction of intervening 
metabolic functions targeting the prevention of 
AD, we provide the first evidence-based 
comparison of effective interventions, concluding 
that exercise has the highest priority. Although 
the beneficial effect of exercise was obtained 
even under HFD, the magnitude and the nature 
(i.e. voluntary vs. forced, aerobic vs. 
anaerobic) of the exercise required to prevent 
HFD-induced AD progression should be 
elucidated in future studies. Since metabolic 
dysfunctions are epidemiologically considered 
to be risk factors of sporadic AD, 
evidence-based interventions for metabolic 
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Fig. 1. Diet control ameliorated HFD-induced obesity and diabetic conditions compared with exercise 
(A) Schematic presentation of the interventions targeting metabolic conditions. As described 
previously [7], APPSwe/Ind mice were maintained with a standard diet in standard laboratory cages 
until 2–3 months old. Then, age- and sex-matched mice were separated into 5 groups. In the control 
group, the mice were induced with a standard diet in standard laboratory cages for 20 weeks (control 
APP mice) (top row, n = 9). In the HFD-induced group, mice were fed HFD in standard laboratory 
cages for 20 weeks (APP-HFD mice) (2
nd
 row, n = 10). In the HFD with exercise-induced group, mice 
spent 10 weeks in standard laboratory cages, and then spent 10 weeks in enrichment cages with HFD 
(Ex: exercise; APP-HFD+Ex mice) (3
rd
 row, n = 8). As a novel intervention, in the 
diet-control-induced group, after 10 weeks of HFD, we used a standard diet for another 10 weeks (Dc: 
diet control; APP-HFD+Dc mice) (4
th
 row, n = 7). In the combination group with exercise plus diet 
control, mice spent 10 weeks in standard laboratory cages with HFD and then spent 10 weeks in 
enrichment cages with a standard diet (APP-HFD+Ex+Dc mice) (bottom row, n = 7). After 20 weeks, 
metabolic conditions of these mice were analyzed, followed by ethological, histochemical and 
biochemical analyses targeting AD pathophysiology. 
(B) Relative body weight changes over 20 weeks. The body weight 2 weeks before each diet was 
regarded as the baseline (100%). Diet control and its combination with exercise significantly inhibited 
the HFD-induced increase of body weight.  
(C) Blood glucose levels during glucose tolerance test after an intra-peritoneal injection of glucose (2 
g/kg body weight). The fasting glucose level and glucose tolerance in APP-HFD+Dc mice (F (4,159) = 
26.49, p < 0. 001) and APP-HFD+Ex+Dc mice (p < 0.001) were clearly improved. 
(D) Serum insulin levels during fasting. The serum insulin levels in APP-HFD+Dc mice (F (4, 36) = 9.3, 
p = 0.003) and APP-HFD+Ex+Dc mice (p < 0.001) were significantly decreased compared with that in 
APP-HFD mice.  
 
Fig. 2. Diet control ameliorated HFD-induced lipid dysfunction compared with exercise 
(A) Plasma total cholesterol levels. The total cholesterol levels in APP-HFD+Dc mice (F (4, 36) = 30.29, 
p < 0.001) and APP-HFD+Ex+Dc mice (p < 0.001) were significantly decreased compared with the 
level in APP-HFD mice. 
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(B) Plasma HDL cholesterol levels. The HDL cholesterol levels in APP-HFD+Dc mice (F (4, 36) = 
30.96, p < 0.001) and APP-HFD+Ex+Dc mice (p < 0.001) were significantly decreased compared with 
the level in APP-HFD mice. 
(C) Plasma triglyceride levels. There was no difference among control, APP-HFD, APP-HFD+Ex, 
APP-HFD+Dc and APP-HFD+Ex+Dc mice (F (4, 36) = 1.65, n.s.). 
 
Fig. 3. Exercise ameliorated HFD-induced memory deficit compared with diet control 
(A) Escape latency in the acquisition phase. APP-HFD+Ex mice took shorter time to the platform than 
APP-HFD+Dc mice.  
(B) The time to the target quadrant in the probe trial phase. APP-HFD+Ex mice took shorter time to 
the platform than APP-HFD+Dc mice (F (4, 36) = 23. 03, p = 0. 041).  
(C) The number of entries into the target quadrant in the probe trial phase. APP-HFD+Dc mice were 
significantly impaired in the number of times they crossed the platform compared with APP-HFD+Ex 
mice (F (4, 36) = 13.59, p = 0. 013).  
 
Fig. 4. Exercise ameliorated HFD-induced Aβ accumulation compared with diet control 
(A) Immunohistochemical analysis using anti-Aβ (6E10) antibody. Representative images of 
Aβ-immunostained hippocampus sections from control APP, APP-HFD, APP-HFD+Ex, 
APP-HFD+Dc and APP-HFD+Ex+Dc induced mice, respectively. Scale bar, 2 mm  
(B) Cerebral Aβ loads determined by immunohistochemical and morphometric analyses. The cerebral 
Aβ deposition was significantly decreased in APP-HFD+Ex mice compared with that in 
APP-HFD+Dc mice (F (4, 15) = 18.35, p = 0. 039).  
(C) The amount of Aβ oligomers in the TBS-soluble fractions of control-APP, APP-HFD, 
APP-HFD+Ex, APP-HFD+Dc and APP-HFD+Ex+Dc mice analyzed by filter trap assay using anti-Aβ 
oligomer (A11) antibody. As described in [12], the Aβ monomer and low weight oligomers passed 
through the membrane pore (200 nm pore-sozed) and high weight oligomers were detected in this 
assay. 
(D) Statistical analysis of dot density. The average band density of the control APP samples was 
regarded as 100% and that of other groups was relatively indicated. The relative density of 
APP-HFD+Ex mice was significantly decreased compared with that of APP-HFD+Dc mice (F (4, 10) = 
47.42, p = 0.011).  
 
Fig. 5. Both diet control and exercise reduced APP CTFβ accumulation 
(A) Immunoblotting analysis of APP full length, APP CTFand CTFβ. APP full length and APP 
CTFs (CTFand CTFβ) were detected by anti-APP C-terminus antibody. β-actin was detected as 
loading control. Long exposure indicated that a same film was exposed longer time. The mark of * 
indicates glycosylated APP full length. To analyze APP CTFs in detail, two kinds of gels (5-20 % 
polyacrylamide gradient gels and 4-12% NuPAGE Bis-Tris gels) were used. Unfortunately, we could not 
clarify the mobility of CTFs bands caused by phosphorylation presumably because of the gel 
conditions of our experiment. 
(B) Statistical analysis of APP full length. The band of APP full length was normalized by that of 
β-actin. The band density of the control was regarded as 100% and that of other groups was relatively 
indicated. There was no statistically significant difference among control APP, APP-HFD, 
APP-HFD+Ex, APP-HFD+Dc and APP-HFD+ Ex+Dc mice (F (4, 10) = 0.47, n.s.).  
(C) Statistical analysis of APP CTFβ. The band of APP CTFβ was normalized by that of APP full 
length. The band density of APP CTFβ in APP-HFD mice was increased compared with that in control 
APP mice. However, the band density of APP CTFβ in APP-HFD+Ex (F (4, 10) = 4.27, p = 0.003), 
APP-HFD+Dc (p = 0.021) and APP-HFD+Ex+Dc (p = 0.023) mice were significantly decreased 
compared with that in APP-HFD mice. There was no difference between APP CTFβ in APP-HFD+Ex 
mice and that in APP-HFD+Dc mice. 
(D) Statistical analysis of APP CTF. The band of APP CTF was normalized by that of APP full 
length. The band density of APP CTF in APP-HFD mice was increased compared with that in 
control APP mice. The band density of APP CTF in APP-HFD+Ex (F (4, 10) = 4.36, p = 0.034), 
APP-HFD+Dc (p = 0.014) and APP-HFD+Ex+Dc (p = 0.024) mice were significantly decreased 
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compared with that in APP-HFD mice. There was no difference between APP CTF in APP-HFD+Ex 
mice and that in APP-HFD+Dc mice. 
 
Fig. 6. Exercise specifically rescued the HFD-induced deterioration of neprilysin activity  
(A) In vitro enzyme activity assay of neprilysin using the fluorescence substrate. The activity of 
neprilysin in APP-HFD mice tends to be decreased compared with that in control APP mice (F (4, 15) = 
5.58, p = 0.061). On the other hand, neprilysin activity in APP-HFD+Ex mice was significantly higher 
than that in APP-HFD (p = 0.023) or that in APP-HFD+Dc mice (p = 0.032). 
(B) Significant correlation was established by comparing the activity of neprilysin and the level of 
cerebral Aβ deposition, using Pearson’s correlation coefficients. The activity of neprilysin was 
negatively correlated with the level of accumulated Aβ (r = -0.782, p = 0.00003).  
 
Fig. 7. Schematic presentation of our study 
(A) The classification of the results in the present study. The items we analyzed in this report are 
included in the left lane. On the other hand, the effect of amelioration is showed in the right lane. As 
shown in this chart, diet control > exercise indicated that diet control ameliorated better than exercise. 
Diet control significantly improved HFD-induced metabolic conditions, including obesity, hyperinsulinemia 
and hypercholesterolemia, better than exercise. However, exercise decreased soluble Aβ oligomers as well 
as deposited Aβ and ameliorated memory impairment better than diet control. 
(B) Schematic presentation of our hypothesis – how diet control or exercise ameliorated HFD-induced 
memory deficits and Aβ accumulation. HFD leads to glucose intolerance and hyperglycemia, which may 
lead to the up-regulation of -secretase activity. This up-regulation increases soluble Aβ oligomers as well 
as deposited Aβ levels, followed by memory deficit [7]. On the other hand, both diet control and exercise 
ameliorate HFD-induced glucose intolerance and hyperglycemia, thereby decreasing soluble Aβ oligomer 
and fibrillar Aβ levels by inhibiting Aβ production. However, exercise specifically strengthens the enzymatic 
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